Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 11833216 Anti-EDB antibodies and antibody-drug conjugates

Patent 11833216 was granted and assigned to Pfizer on December, 2023 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

0

Patent attributes

Patent Applicant

0

Current Assignee

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Patent Inventor Names

Chakrapani Subramanyam0

Kimberly Ann Marquette0

Andrea Therese Hooper0

Hans-Peter Gerber0

Chad Michael May0

Date of Patent

December 5, 2023

0

Patent Application Number

181667740

Date Filed

February 9, 2023

0

Patent Citations

US Patent 8491906 Selective targeting of tumor vasculature using antibody molecules

0

US Patent 8679488 Targeting of bone marrow neovasculature

0

US Patent 8703143 Antibodies of the ED-B domain of fibronectin, their construction and uses

0

US Patent 8828401 Cytotoxic peptides and antibody drug conjugates thereof

0

US Patent 8945571 Targeted immunoconjugates

0

US Patent 9096670 Antibodies of the ED-B domain of fibronectin, their construction and uses

0

US Patent 9138486 Cytotoxic peptides and antibody drug conjugates thereof

0

US Patent 9181347 Antigen associated with the neovasculature of tumour metastases

0

...

Patent Primary Examiner

0

Patent abstract

The present invention provides antibodies and antibody-drug conjugates that bind to the extra domain B splice variant of fibronectin 1 and methods for preparing and using the same.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11833216 Anti-EDB antibodies and antibody-drug conjugates

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool